Fight insulin-resistance

At THAC, we are developing a candidate molecule to fight insulin-resistance and prevent the development of age-related diseases in particular type II diabetes, Alzheimer’s disease and non-alcoholic steatohepatitis (NASH).

Aging is a major and inevitable risk factor for insulin resistance. With the growing aging population and sedentary life style, insulin-resistance based diseases are a major health and economic burden

Addressing an unmet medical need

Currently, no available molecule has a market authorization for insulin resistance. Only the metformin, exclusively delivered to patients with type II diabetes, acts on insulin resistance but is hardly tolerated since 30% of the patients stop the treatment due to side effects.

While it is implicated in many other age-related diseases, insulin resistance is only addressed in type II diabetes patients. At THAC we aim to develop an innovative strategy, specifically targeting insulin resistance to impede the development of age-related diseases linked to insulin resistance

Age-related diseases and insulin resistance

  • Diabetes

Insulin resistance preceeds diabetes in a state called prediabetes. Insulin resistance is counteracted by an increased insulin production by the pancreatic beta cells until their exhaustion. This implicates a critical high level of glucose in blood (fasting plasma glucose between 1,10 and 1,25 g/l) ending in diabetes.

Worldwide, 318 millions of people are prediabetic obeses and 425 millions are diabetics. According to the international diabetes federation, the cost for diabetes patients (from 18 to 99 years old) reaches about $850 billions and will reach $950 billions by 2045.

  • Non-alcoholic steatohepatitis (NASH)

NASH is a condition characterized by abnormal fat storage and inflammation in the liver. Insulin resistance seems to be the first cause of the disease by increasing lipolysis in the adipose tissue and so the accumulation of fat in the liver.

The prevalence of NASH in the worldwide adult population is estimated at 12% (Williams CD, 2011). The direct cost of the disease has been evaluated in USA, France, Italy, England and Germany and reaches more than $10 billions (Younossi ZM, 2016).

  • Alzheimer’s Disease (AD)

AD is a neurodegenerative disease characterized by cognitive and behaviour impairements. The hallmarks of the disease are the presence of amyloidosis deposits and degenerative neurofibers mainly in the hyppocampus -area implicated in the memory- but also in other area of the cerebral cortex involved in thinking and decision making. Several risk factors are linked to dementia in AD including aging, obesity, insulin resistance and oxydatif stress .

Worldwide, 46 millions of people have dementia with 54 to 80 % of patients with AD for a global cost of $600 billions (Flavia Mayer, 2018); (Wilson, 2012).